CardioExchange Archive

April 17th, 2012

What’s in a Name? Go for the Generic

Nicholas Downing, MD

A recent report published in the Archives of Internal Medicine highlights some “low-hanging fruit” for anyone trying to deliver more cost-effective healthcare. The authors (I am the first author and Harlan Krumholz, CardioExchange editor-in-chief, is the senior author) describe how branded formulations of fenofibrate — marketed by Abbott as Tricor and Trilipix — account for the vast majority […]

---

August 10th, 2011

Rethinking Trilipix — And the Process for Approving Lipid-Modifying Drugs

Sanjay Kaul, MD

Editor’s Note: In an article published in the New England Journal of Medicine, three members of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (Allison Goldfine, Sanjay Kaul, and William Hiatt) offer their perspective on the May 19 committee meeting to review the controversial ACCORD-Lipid Study. Here, one of those authors, Sanjay Kaul, provides his […]

---

May 17th, 2011

FDA Reviewers Scrutinize ACCORD and Trilipix

Larry Husten, PHD

The FDA has released the agenda, questions, roster, and briefing materials for Thursday’s meeting of the Endocrinologic and Metabolic Drugs Advisory Committee in which the ACCORD trial and the fate of Abbott’s Trilipix (fenofibric acid) will be discussed. The key questions on which the advisory committee members will be asked to vote are: Should the FDA require […]

---